Navigation Links
Thomson Scientific Introduces a New Quarterly Report Identifying the 'Movers and Shakers' in the U.S. Generics Industry
Date:1/8/2008

Report Draws On Strategic Intelligence and Competitive Analysis Information

From Newport Horizon Global(TM)

PHILADELPHIA and LONDON, Jan. 9 /PRNewswire-FirstCall/ -- Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, has released the first issue of Movers and Shakers. This newest report in the Pharma Matters series analyzes the U.S. generics market from July to September 2007, profiles some of the companies breaking into the market, and highlights molecule patents currently being challenged.

Movers and Shakers reviews the U.S. generics market using strategic intelligence and competitive analysis information drawn from Thomson Scientific's Newport Horizon Global, the critical product targeting and global business development system from the industry authority on the global generics market, in order to assess one of the world's most important pharmaceutical markets.

"Because of the dynamic nature of the generics market in the U.S., the common perception is that the market is relatively easy to break into," said Kate Kuhrt, director, Generics and API Intelligence, Thomson Scientific. "However, our research has shown that there is huge competition between the incumbents and new companies vying for a slice of the market, and clearly there will be winners and losers. Ours is the first quarterly report to identify the real 'movers and shakers' within the generics market."

The first quarterly report covers the period of July to September 2007, and highlights the key indicators of the state of play of the industry. These are:

Abbreviated New Drug Applications (ANDA): An ANDA is the first step in the process a company needs to follow in order to release a generic drug in the U.S. and is submitted to the FDA to prove that the generic version is equivalent to the brand name drug (reference listed drug).

Paragraph IV challenges: A generic company may obtain FDA approval before patent expiry if it certifies its product does not infringe the listed patents or the patents are invalid (paragraph IV certification). In addition, the first company to file an ANDA with paragraph IV certification is awarded a 180-day period of exclusivity for the ensuing generic product, giving the filer an important competitive advantage. Bioequivalent generic versions of drugs that are not protected by patents can be produced and marketed in the U.S. by any company, subject to FDA approval.

Who Are the Movers and Shakers This Quarter?

Molecules recently exposed to paragraph IV challenges: Big Pharma companies such as sanofi-aventis, Eli Lilly, Hoffmann-La Roche and AstraZeneca all saw challenges in the period from July to September on molecules they have patented.

Companies taking their first steps into the US generics industry: The report highlights companies that were felt to be of significant interest. This quarter, the report focuses on Dabur India Ltd, who launched a Paragraph IV challenge on the drug oxaliplatin, Zhejiang Huahai Pharmaceutical Group Co Ltd, a Chinese company that has received tentative approval for nevirapine 200mg tablets under the President's Emergency Plan for Aids Relief (PEPAR) program, and GeneraMedix Pharmaceuticals Inc., an American company based in New Jersey that has received FDA approval for a selection of new products.

"The global stakes involved in the US generics market become evident when you see that the top country filing ANDAs in the US is India, and the company recorded as having the most Paragraph IV patent challenges is Teva, an Israeli Pharma company," added Kuhrt. "Clearly, the message is that American companies cannot presume that they will have a home advantage in this market."

About This Quarterly Report:

Data for this report was compiled and analyzed using Newport Horizon Global(R) a critical product targeting and global business development system from Thomson Scientific. Created specifically for generic pharmaceutical companies and strategic API manufacturers, it allows them to identify and evaluate product opportunities worldwide, ensuring they will be the first to find the generic product and niche opportunity, first to make the deal, and first to get to market.

For a copy of the full report with analysis, visit:

(To view the following url, please copy and paste it into a new browser.) http://scientific.thomson.com/thomsonpharma/media/pdfs/tpqr/m-a-s-jul- sep07.pdf

About The Thomson Corporation

The Thomson Corporation (http://www.thomson.com) is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at scientific.thomson.com.


'/>"/>
SOURCE The Thomson Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare
2. Saint Barnabas Health Care System Expands Business Relationship with Thomson Healthcare
3. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
4. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
5. Thomson Scientific Takes a Fresh Look at Multiauthor Papers
6. Thomson Healthcare Study Finds That Hospitals Delivering High-Quality Heart Care Are Efficient and Cost Effective, Too
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - a Quarterly Review of Scientific Literature on Drugs and Therapies From July - September 2007
8. Thomson Healthcare Launches Application That Assesses Physician Performance
9. Contract Renewal Extends Thomson Healthcares Long-Standing Relationship with University Hospitals
10. Thomson Scientific Launches Confessions ... of a User Campaign Asking Are You the New Face of Research?
11. Thomson Scientific Ranks Australian Universities and Research Institutes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Killeen, Texas (PRWEB) , ... May 27, 2016 , ... ... with satisfying Army body fat composition regulations. This is the first time that ... are normally screened at least every six months to ensure they meet the prescribed ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... scholarships to students studying complementary medicine. Allison Outerbridge is this year’s Life ... award on May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook ... Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the ... is their favorite way to cook a hot dog, far outpacing other cooking methods ...
(Date:5/26/2016)... Missouri (PRWEB) , ... May 26, 2016 , ... ... quality and clinical outcomes, hosted members and suppliers for its inaugural Member Conference ... focus on their mission of elevating the operational health of America’s healthcare providers. ...
(Date:5/26/2016)... Washington, D.C. (PRWEB) , ... May 26, 2016 , ... ... the men and women who lost their lives in military battle for the country. ... discount cards in 2015 to provide more programs that empower independence for disabled military ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that ... at two upcoming investor conferences: SeeThru Equity MicroCap ... New York City , NY When: ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, 109 ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
Breaking Medicine Technology: